Serotype and clonal distribution dynamics of invasive pneumococcal strains after PCV13 introduction (2011-2016): surveillance data from 23 sites in Catalonia, Spain
Autor/a
Ludwig, Guillermo
Garcia-Garcia, Selene
Lanaspa, Miguel
Ciruela, Pilar
Esteva, Cristina
Fernandez de Sevilla, Mariona
Diaz-Conradi, Alvaro
Marti, Carmina
Motje, Montse
Galles, Carme
Morta, Montse
Izquierdo, Conchita
Moraga-Llop, Fernando
Campins, Magda
Salleras, Luis
Jané, Mireia
Domínguez, Ángela
Garcia-Garcia, Juan Jose
Catalan Study Group of Invasive Pneumococcal Disease
Data de publicació
2020-02ISSN
1932-6203
Resum
Background: The objective of this study is to describe incidence and shifts of serotype and clonal distribution of invasive Streptococcus pneumoniae strains in four different age groups (<5 years, 5–17 years, 18–64 years and >65 years) during a period of intermediate PCV13 vaccination coverage (2011–2016) in Catalonia, Spain. Methods: We included all pneumococcal strains systematically sent to the Catalan support laboratory for molecular surveillance of invasive pneumococcal disease (IPD) located at Hospital Sant Joan de Deu, Barcelona. Two study periods were considered: 2011–13, early PCV13 vaccination period (EVP) and 2014–2016, late vaccination period (LVP). Results: A total of 2142 strains were included in the study. Five years after intermediate introduction of PCV13 in our population, a significant decrease of overall incidence of IPD in children <5 years was observed (incidence rate ratio 0.5, 95% confidence interval 0.4–0.8). However, in seniors older than 65 years, a significant increase of overall incidence of IPD was observed (IRR 1.4, 95% CI 1.1–1.7). The contribution of PCV13 vaccine serotypes to IPD declined significantly in all age groups: from 59% to 38.1% in <5 years; 82.7% to 59% in 5–17 years, 47.8% to 34.1% in 18–64 years and 48.2% to 37% in >65 years. Results found when comparing both periods were consistent with IRRs observed year by year. In children <5 years, the three major serotypes detected were 1, 24F and 19A in EVP vs 24F, 14 and 10A in LVP. Among patients 5–17 years the first three serotypes were 1, 12F and 14 both in EVP and LVP. Among adults 18–64, the three major serotypes detected were 1, 12F and 8 vs 8, 12F and 3, respectively. Finally, in patients >65 years the most frequently isolated serotypes were 3, 19A and 7F vs 3, 14 and 12F, respectively. Regarding clonal complexes (CCs) expressing mainly PCV13 serotypes, significant decreases of the proportions of CC306, CC191 and CC320 were observed, while CC156 showed a significant increase. As for CCs expressing mostly non-PCV13 serotypes, significant increases in ST989, CC53 and CC404 were showed. Conclusions: Despite low vaccine coverage in our setting a significant decrease of incidence of IPD was observed in children younger than 5 years. The modest indirect protection against vaccine serotypes causing IPD in elderly indicate the need for the inclusion of more serotypes in future high-valent PCV and vaccinating old adults should be considered.
Tipus de document
Article
Versió del document
Versió publicada
Llengua
English
Matèries (CDU)
61 - Medicina
Paraules clau
Vacunes
Pneumococs
Microbiologia
Vacunas
Neumococos
Microbiología
Vaccines
Pneumococcus
Microbiology
Pàgines
16
Publicat per
Public Library of Science
Col·lecció
15; 2
Publicat a
PLoS One
Citació
Ludwig, Guillermo; Garcia-Garcia, Selene; Lanaspa, Miguel [et al.]. Serotype and clonal distribution dynamics of invasive pneumococcal strains after PCV13 introduction (2011-2016): surveillance data from 23 sites in Catalonia, Spain. PLoS One, 2020, 15(2), e0228612. Disponible en: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228612>. Fecha de acceso: 8 feb. 2020. DOI: 10.1371/journal.pone.0228612
Aquest element apareix en la col·lecció o col·leccions següent(s)
- Ciències de la Salut [740]
Drets
© 2020 Ludwig et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com https://creativecommons.org/licenses/by/4.0/